The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s showing significant promise in clinical trials for managing obesity. Unlike some available weight loss treatments, retatrutide appears to deliver a greater substantial decrease in body size and benefit metabolic function, particu